What one share of Absci holds
We are a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics. Our integrated drug creation platform combines Origin-1, our generative design model, with rapid validation using our lab-in-the-loop.
Absci’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$0.80 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.72 |
| Cash and investments | $1.17 |
| Debt | $0.01 |
| Book value | $1.43 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.31 | −$3.19 | $0.14 | −$0.85 | — | −$5.00 |
| 2021 | $0.10 | −$2.08 | $0.77 | −$1.99 | — | $3.95 |
| 2022 | $0.06 | −$1.15 | $0.18 | −$1.07 | — | $2.97 |
| 2023 | $0.06 | −$1.20 | $0.01 | −$0.71 | — | $1.89 |
| 2024 | $0.04 | −$0.94 | $0.00 | −$0.66 | — | $1.55 |
| 2025 | $0.02 | −$0.84 | $0.01 | −$0.69 | — | $1.24 |
Common questions about Absci
How much does one share of Absci earn?
Over the last 12 months, Absci lost $0.80 for each share on $0.01 of sales.
Does Absci pay a dividend?
Absci didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Absci’s book value per share?
Absci’s book value is $1.43 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Absci have?
Each share of Absci has $1.17 of cash and investments and $0.01 of debt, as of June 30, 2026.
What is Absci’s free cash flow per share?
−$0.72 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Absci bought back shares?
Absci’s share count rose about 783% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.